PURPOSE: Identifying genes differentially expressed in nondysplastic BE (NDBE) from those expressed in high-grade dysplasia (HGD) should be of value in improving our understanding of this transition and may yield new diagnostic and/or prognostic markers. The aim of this study was to determine the differential transcriptome of HGD compared with NDBE through gene microarray analysis of epithelial cells microdissected from archival tissue specimens. EXPERIMENTAL DESIGN: Laser capture microdissection was used to isolate epithelial cells from adjacent inflammatory and stromal cells. Epithelial mRNA was extracted from areas of NDBE and HGD in matched biopsies from 11 patients. mRNA was reverse transcribed and applied on Affymetrix cDNA microarray chips customized for formalin-exposed tissue. For a subset of these genes, differential gene expression was confirmed by real-time PCR and immunohistochemistry. RESULTS: There were 131 genes overexpressed by at least 2.5-fold in HGD versus NDBE and 16 genes that were underexpressed by at least 2.5-fold. Among the overexpressed genes are several previously shown to be increased in the neoplastic progression of BE, as well as novel genes such as lipocalin-2, S100A9, matrix metallopeptidase 12, secernin 1, and topoisomerase IIalpha. Genes decreased in dysplastic epithelium include MUC5AC, trefoil factor 1 (TFF1), meprin A, and CD13. Real-time PCR validated the changes in expression in 24 of 28 selected genes. Immunohistochemistry confirmed increased protein expression for topoisomerase IIalpha, S100A9, and lipocalin-2 and decreased expression of TFF1 across the spectrum of BE-associated dysplasia from NDBE through adenocarcinoma. CONCLUSIONS: This is the first study to identify epithelial genes differentially expressed in HGD versus NDBE in matched patient samples. The genes identified include several previously implicated in the pathogenesis of BE-associated dysplasia and new candidates for further investigation.
PURPOSE: Identifying genes differentially expressed in nondysplastic BE (NDBE) from those expressed in high-grade dysplasia (HGD) should be of value in improving our understanding of this transition and may yield new diagnostic and/or prognostic markers. The aim of this study was to determine the differential transcriptome of HGD compared with NDBE through gene microarray analysis of epithelial cells microdissected from archival tissue specimens. EXPERIMENTAL DESIGN: Laser capture microdissection was used to isolate epithelial cells from adjacent inflammatory and stromal cells. Epithelial mRNA was extracted from areas of NDBE and HGD in matched biopsies from 11 patients. mRNA was reverse transcribed and applied on Affymetrix cDNA microarray chips customized for formalin-exposed tissue. For a subset of these genes, differential gene expression was confirmed by real-time PCR and immunohistochemistry. RESULTS: There were 131 genes overexpressed by at least 2.5-fold in HGD versus NDBE and 16 genes that were underexpressed by at least 2.5-fold. Among the overexpressed genes are several previously shown to be increased in the neoplastic progression of BE, as well as novel genes such as lipocalin-2, S100A9, matrix metallopeptidase 12, secernin 1, and topoisomerase IIalpha. Genes decreased in dysplastic epithelium include MUC5AC, trefoil factor 1 (TFF1), meprin A, and CD13. Real-time PCR validated the changes in expression in 24 of 28 selected genes. Immunohistochemistry confirmed increased protein expression for topoisomerase IIalpha, S100A9, and lipocalin-2 and decreased expression of TFF1 across the spectrum of BE-associated dysplasia from NDBE through adenocarcinoma. CONCLUSIONS: This is the first study to identify epithelial genes differentially expressed in HGD versus NDBE in matched patient samples. The genes identified include several previously implicated in the pathogenesis of BE-associated dysplasia and new candidates for further investigation.
Authors: Renata A Coudry; Sibele I Meireles; Radka Stoyanova; Harry S Cooper; Alan Carpino; Xianqun Wang; Paul F Engstrom; Margie L Clapper Journal: J Mol Diagn Date: 2007-02 Impact factor: 5.568
Authors: F M Selaru; T Zou; Y Xu; V Shustova; J Yin; Y Mori; F Sato; S Wang; A Olaru; D Shibata; B D Greenwald; M J Krasna; J M Abraham; S J Meltzer Journal: Oncogene Date: 2002-01-17 Impact factor: 9.867
Authors: M K Hong; W B Laskin; B E Herman; M H Johnston; J J Vargo; S M Steinberg; C J Allegra; P G Johnston Journal: Cancer Date: 1995-01-15 Impact factor: 6.860
Authors: E Montgomery; M P Bronner; J R Goldblum; J K Greenson; M M Haber; J Hart; L W Lamps; G Y Lauwers; A J Lazenby; D N Lewin; M E Robert; A Y Toledano; Y Shyr; K Washington Journal: Hum Pathol Date: 2001-04 Impact factor: 3.466
Authors: Luciana I Gomes; Gustavo H Esteves; Alex F Carvalho; Elier B Cristo; Roberto Hirata; Waleska K Martins; Sarah M Marques; Luiz P Camargo; Helena Brentani; Adriane Pelosof; Cláudia Zitron; Rubens A Sallum; André Montagnini; Fernando A Soares; E Jordão Neves; Luiz F L Reis Journal: Cancer Res Date: 2005-08-15 Impact factor: 12.701
Authors: Dorine A Bax; Peter D Siersema; Jelle Haringsma; Ernst J Kuipers; Arthur J M Vos; Herman Van Dekken; Arnoud H M Van Vliet; Johannes G Kusters Journal: Scand J Gastroenterol Date: 2007-08 Impact factor: 2.423
Authors: Frank J G M Kubben; Cornelis F M Sier; Lukas J A C Hawinkels; Harald Tschesche; Wim van Duijn; Kim Zuidwijk; Johan J van der Reijden; Roeland Hanemaaijer; Gerrit Griffioen; Cornelis B H W Lamers; Hein W Verspaget Journal: Eur J Cancer Date: 2007-07-02 Impact factor: 9.162
Authors: K K Wang; J M Tian; E Gorospe; J Penfield; G Prasad; T Goddard; M Wongkeesong; N S Buttar; L Lutzke; S Krishnadath Journal: Dis Esophagus Date: 2012-03-12 Impact factor: 3.429
Authors: Lei Wei; Katsuaki Kanbe; Mark Lee; Xiaochun Wei; Ming Pei; Xiaojuan Sun; Richard Terek; Qian Chen Journal: Dev Biol Date: 2010-03-04 Impact factor: 3.582
Authors: Sorcha Finnegan; Joanne Robson; Paul M Hocking; Manir Ali; Chris F Inglehearn; Alan Stitt; William J Curry Journal: Mol Vis Date: 2010-01-11 Impact factor: 2.367